Défi diagnostique de la dermatomyosite à anti-MDA-5 avec insuffisance respiratoire pendant la pandémie de COVID-19 : A propos d’un cas
PDF (English)

Mots-clés

Anticorps anti-MDA5,
Dermatomyosite
Pneumopathie interstitielle diffuse
Insuffisance respiratoire
SARS-CoV-2
COVID-19

Catégories

Comment citer

Zamali, I., Meddeb, Z. ., Bejar, D. ., Korbi, F., Ben Hmid, A. ., Hidri, M., Larbi, T., Hamzaoui, S., Bouslama, K., & Ben Ahmed, M. (2024). Défi diagnostique de la dermatomyosite à anti-MDA-5 avec insuffisance respiratoire pendant la pandémie de COVID-19 : A propos d’un cas. Revue Tunisienne De Biologie Clinique, 31(1). Consulté à l’adresse https://rtbc.org.tn/ojs/index.php/rtbc/article/view/250

Résumé

Contexte : Les anticorps anti-MDA5 sont fortement associés à la dermatomyosite amyopathique clinique. Les patients développent fréquemment une pneumopathie interstitielle diffuse (PID) pouvant conduire à une insuffisance respiratoire. Le pronostic sombre rend le diagnostic précoce et précis crucial. Présentation du cas : Nous présentons le cas d’un patient nord-africain ayant subi un diagnostic retardé et présentant une insuffisance respiratoire hypoxémique sévère. Dans le contexte de la pandémie de COVID-19, cette présentation clinique peut poser un problème de diagnostic différentiel. Le patient a reçu une thérapie par bolus de stéroïdes ainsi que du cyclophosphamide avec une amélioration progressive de l’état respiratoire. Conclusions : Ce cas met en lumière l’importance du dépistage des anticorps anti-MDA5 chez les patients hypomyopathiques présentant une PID à progression rapide.

PDF (English)

Références

Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-Associated Dermatomyositis: Expanding the clinical

spectrum. Arthritis Care Res. 2013;65(8):1307-1315.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571-1576.

Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology.2020;95(1):e70-8.

Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol [Internet]. 20 oct 2021 [cité 12 avr 2024];12. Disponible sur: https://www.frontiersin.org/ journals/immunology/articles/10.3389/fimmu.2021.773352/full.

Koichi Y, Yamaguchi A, Onuki Y, Itai M, Kashiwagi C, Takehara K, et al. Clinical features of dermatomyositis associated with anti-MDA-5 antibodies by age.2020;31(1):177-185.

Gupta P, Kharbanda R, Lawrence A, Gupta L.Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: Diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic. Egypt Rheumatol. 2021;43(4):271-274.

Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev [Internet]. 31 déc 2018 [cité 15 sept 2021];27(150). Disponible sur:

https://err.ersjournals.com/content/27/150/180076.

Li J, Liu Y, Li Y, Li F, Wang K, Pan W, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis. J Dermatol. 2018;45(1):46-52.

Labrador-Horrillo M, Martinez MA, SelvaO’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 Antibodies in a

Large Mediterranean Population of Adults with Dermatomyositis. J Immunol Res. 2014;2014:290797.

Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatol Oxf Engl. 2020;59(8):2109 14.

Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of Antisynthetase Antibodies Specificities on

Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 2019;8(11):2013.

Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39(11):1971-1981.

Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011;10(9):509-13.

Lv C, You H, Xu L, Wang L, Yuan F, Li J, et al. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly

Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk. J Rheumatol. 2023;50(2):219-226.

Kondo Y, Kaneko Y, Takei H, Tamai H, Kabata H, Suhara T, et al. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still’s disease. Clin Exp Rheumatol. 2021;8.

Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;56(3):2001618.

Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol Oxf Engl. 2012;51(9):1563-1570.

Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41(6):1021-1036.

Sampaio NG, Chauveau L, Hertzog J, Bridgeman A, Fowler G, Moonen JP, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep.

;11(1):13638.

Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep [Internet]. 12 janv 2021 [cité 17 déc 2021];34(2). Disponible sur: https://www.cell.com/cellreports/abstract/S2211-1247(20)31617-X

Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219-243.

Liu C, Wang Q, Wang Y, Wang G, Wang L, Chen H, et al. Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study [Internet]. 2020 août [cité 17 déc 2021] p.2020.07.29.20164780. Disponible sur: https:// www. medrxiv.org/content/10.1101/2020.07.29.20164780v2.

Maiti AK. The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics. 2020;72(6-7):387-391.

Dias Junior AG, Sampaio NG, Rehwinkel J. A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2019;27(1):75-85.

Suárez-Calvet X, Toquet S, Danel C, Couvelard A, Roland P, Uzunhan Y, et al. The pathogenesis of dermatomyositis associated to MDA5 autoantibodies: An in vitro and in vivo study. Neuromuscul Disord. 2016;26:S145-6.

Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496-502.

Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925-933.

Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021;40(6):2311-2317

Creative Commons License

Ce travail est disponible sous la licence Creative Commons Attribution 4.0 International .

(c) Tous droits réservés Imen Zamali, Zeineb Meddeb, Dorra Bejar, Fatma Korbi, Ahlem Ben Hmid, Mouldi Hidri, Thara Larbi, Saloua Hamzaoui, Kamel Bouslama, Melika Ben Ahmed 2024